Dicerna Pharmaceuticals, Inc. logo
Dicerna Pharmaceuticals, Inc. DRNA

Dicerna Pharmaceuticals, Inc. Financial Ratios 2011-2026 | DRNA

Annual Financial Ratios Dicerna Pharmaceuticals, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-14.9 -11.1 -6.3 -3.5 -0.9 -2.1 -7.1 -41.3 - -

P/S

10.2 55.7 90.5 92.6 182.6 724.5 - - - -

EV/EBITDA

-14.4 -9.3 -8.3 -2.4 -0.6 -1.2 -7.2 -42.6 - -

PEG

-1.09 1.11 -0.11 0.13 -0.13 0.71 0.05 -0.55 - -

P/B

12.2 8.7 2.8 2.1 1.3 1.5 3.5 -11.1 - -

P/CF

10.3 -189.1 31.2 -4.6 -1.1 -2.7 -9.3 -67.3 - -

ROE %

-81.85 -79.15 -44.27 -59.31 -144.42 -69.04 -48.75 26.87 - -

ROA %

-15.93 -20.16 -21.72 -49.67 -116.12 -62.82 -46.27 -37.19 - -

ROCE %

-21.36 -36.04 -19.44 -58.12 -144.99 -69.24 -45.81 -41.26 - -

DSO

80.1 3085.7 5958.1 383.4 707.7 105.1 - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Dicerna Pharmaceuticals, Inc., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Amgen Amgen
AMGN
$ 340.0 -0.75 % $ 183 B usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 12.32 -0.24 % $ 3.86 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.27 -1.63 % $ 2.96 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.36 -2.16 % $ 362 M britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.76 4.35 % $ 9.05 B australiaAustralia
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.57 -3.38 % $ 16.1 M usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 2.75 1.48 % $ 7.17 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 3.48 -16.14 % $ 8.76 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Dyadic International Dyadic International
DYAI
$ 0.88 1.66 % $ 31.8 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 89.62 -1.82 % $ 27.2 B germanyGermany
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.67 - $ 196 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.8 7.34 % $ 256 B britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA